133 149

Cited 6 times in

Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation

 Hyung Kwon Byeon  ;  Hwi Jung Na  ;  Yeon Ju Yang  ;  Sooah Ko  ;  Sun Och Yoon  ;  Minhee Ku  ;  Jaemoon Yang  ;  Jae Wook Kim  ;  Myung Jin Ban  ;  Ji-Hoon Kim  ;  Da Hee Kim  ;  Jung Min Kim  ;  Eun Chang Choi  ;  Chang-Hoon Kim  ;  Joo-Heon Yoon  ;  Yoon Woo Koh 
 Oncotarget, Vol.8(1) : 596-609, 2017 
Journal Title
Issue Date
Animals ; Cell Line, Tumor ; Disease Models, Animal ; Drug Resistance, Neoplasm/genetics* ; Epithelial-Mesenchymal Transition/drug effects* ; Epithelial-Mesenchymal Transition/genetics ; Gene Expression ; Humans ; Indoles/pharmacology ; Male ; Mice ; Mutation* ; Phosphatidylinositol 3-Kinases/metabolism ; Protein Kinase Inhibitors/pharmacology* ; Proto-Oncogene Proteins B-raf/antagonists & inhibitors ; Proto-Oncogene Proteins B-raf/genetics* ; Proto-Oncogene Proteins c-akt/metabolism* ; Proto-Oncogene Proteins c-met/antagonists & inhibitors ; Proto-Oncogene Proteins c-met/metabolism* ; Signal Transduction/drug effects ; Sulfonamides/pharmacology ; Thyroid Neoplasms/drug therapy ; Thyroid Neoplasms/genetics ; Thyroid Neoplasms/metabolism ; Thyroid Neoplasms/pathology ; Xenograft Model Antitumor Assays
BRAF mutation ; drug resistance ; epithelial-mesenchymal transition ; molecular targeted therapy ; thyroid cancer
Previously, the authors have identified that c-Met mediates reactivation of the PI3K/AKT pathway following BRAF inhibitor treatment in BRAF (V600E) mutant anaplastic thyroid cancer, thereby contributing to the acquired drug resistance. Therefore dual inhibition of BRAF and c-Met led to sustained treatment response, thereby maximizing the specific anti-tumor effect of targeted therapy. The present study goes one step further and aims to investigate the effect of acquired resistance of BRAF inhibitor on epithelial-to-mesenchymal transition (EMT) in BRAF mutant thyroid cancer cells and the effect of dual inhibition from combinatorial therapy. Two thyroid cancer cell lines, 8505C and BCPAP were selected and treated with BRAF inhibitor, PLX4032 and its effect on EMT were examined and compared. Further investigation was carried out in orthotopic xenograft mouse models. Unlike BCPAP cells, the BRAF inhibitor resistant 8505C cells showed increased expressions of EMT related markers such as vimentin, β-catenin, and CD44. The combinatorial treatment of PLX4032 and PHA665752, a c-Met inhibitor reversed EMT. Similar results were confirmed in vivo. c-Met-mediated reactivation of the PI3K/AKT pathway contributes to the drug resistance to PLX4032 in BRAF (V600E) mutant anaplastic thyroid cancer cells and further promotes tumor cell migration and invasion by upregulated EMT mechanism. Dual inhibition of BRAF and c-Met leads to reversal of EMT, suggesting a maximal therapeutic response.
Files in This Item:
T201702032.pdf Download
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Otorhinolaryngology (이비인후과학교실)
Yonsei Authors
고윤우(Kho, Yoon Woo)
구민희(Ku, Min Hee) ORCID logo https://orcid.org/0000-0002-1674-1474
김다희(Kim, Da Hee) ORCID logo https://orcid.org/0000-0001-7286-1334
김정민(Kim, Jung Min)
김창훈(Kim, Chang Hoon)
변형권(Byeon, Hyung Kwon)
양재문(Yang, Jae Moon) ORCID logo https://orcid.org/0000-0001-7365-0395
윤선옥(Yoon, Sun Och) ORCID logo https://orcid.org/0000-0002-5115-1402
윤주헌(Yoon, Joo Heon)
최은창(Choi, Eun Chang)
RIS (EndNote)
XLS (Excel)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.